3.40Open3.40Pre Close0 Volume200 Open Interest195.00Strike Price0.00Turnover101.78%IV18.22%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry3.40Extrinsic Value100Contract SizeAmericanOptions Type-0.1397Delta0.0051Gamma68.91Leverage Ratio-0.3910Theta-0.0115Rho-9.63Eff Leverage0.0958Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet